Efficacy and effects of Rivaroxaban

Rivaroxaban is a selective inhibitor of FXa, and its activity does not require cofactors (such as antithrombin III). Rivaroxaban inhibits free FXa and prothrombinase activity and has no direct effect on platelet aggregation, but indirectly inhibits thrombin-induced platelet aggregation. By inhibiting FXa, rivaroxaban may reduce thrombin generation.

Rivaroxaban produces a dose-dependent inhibition ofFXa activity. Coagulation tests, such as prothrombin time (PT), activated partial thromboplastin time (aPTT), and HepTest, also increased with increasing dose. In children treated with rivaroxaban, the correlation between anti-factor Xa and plasma concentrations was linear, with a slope approaching 1. The use of anti-FXa activity or coagulation tests to monitor the anticoagulant effect of rivaroxaban is not recommended. Anti-factor Xa activity was similar in adult subjects with normal hepatic function and in subjects with mild hepatic impairment (Child-Pugh class A). The impact of liver impairment beyond this degree on the coagulation cascade and its relationship to efficacy and safety is currently unclear.

RivaroxabanThe original drug is already on the market in China and can be found under Class B medical insurance. SpecificationsThe price of 10mg*5 tablets is around RMB 100. This drug may be sold in domestic pharmacies or hospitals. The Turkish version of rivaroxabanoriginal drug marketed overseas, specifications10mg*10 tablets, is priced around RMB 170 (the price may fluctuate due to exchange rates). The ingredients of the original rivaroxaban drug sold domestically and abroad are basically the same. Currently, there are no generic drugs produced in other countries on the market overseas.